Indeed, there is some evidence that PD-L2 is associated with decreased survival and decreased CD8+ tumor-infiltrating lymphocytes in patients with esophageal cancer and could be a viable treatment target for many cancers, because it has a greater affinity for the PD-1 receptor than PD-L1 [38,39]. The gene discussed is CD8A; the disease is cancer.